Cargando…

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer

Detalles Bibliográficos
Autores principales:	Iwamoto, Genta, Kawahara, Takashi, Yokomizo, Yumiko, Miyoshi, Yasuhide, Yao, Masahiro, Uemura, Hiroji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Second Military Medical University 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356057/ https://www.ncbi.nlm.nih.gov/pubmed/34401340 http://dx.doi.org/10.1016/j.ajur.2020.05.006

Ejemplares similares

Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer
por: Kawahara, Takashi, et al.
Publicado: (2016)

Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy
por: Uemura, Koichi, et al.
Publicado: (2017)

Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide
por: Kumano, Yohei, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy
por: Kawahara, Takashi, et al.
Publicado: (2015)

The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer
por: Tatenuma, Tomoyuki, et al.
Publicado: (2019)

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Uemura, Koichi, et al.
Publicado: (2018)

Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium‐223
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control
por: Sugimura, Rumiko, et al.
Publicado: (2019)

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer
por: Uemura, Koichi, et al.
Publicado: (2016)

A lower psoas muscle index predicts a poorer prognosis in metastatic hormone‐naïve prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2020)

A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL
por: Miyoshi, Yasuhide, et al.
Publicado: (2022)

Ureter metastatic castration-resistant prostate cancer: a case report
por: Tsutsumi, Sohgo, et al.
Publicado: (2017)

Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

The neutrophil-to-lymphocyte ratio (NLR) predicts adrenocortical carcinoma and is correlated with the prognosis
por: Mochizuki, Taku, et al.
Publicado: (2017)

Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical Prostatectomy
por: Maeda, Yoko, et al.
Publicado: (2016)

Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report
por: Shimokihara, Kota, et al.
Publicado: (2018)

Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate‐specific antigen level and improvement in radiographic findings
por: Kawahara, Takashi, et al.
Publicado: (2019)

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2021)

Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study
por: Kawahara, Takashi, et al.
Publicado: (2022)

RANK/RANKL expression in prostate cancer
por: Ohtaka, Mari, et al.
Publicado: (2016)

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel
por: Kawahara, Takashi, et al.
Publicado: (2012)

Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer
por: Ninomiya, Sahoko, et al.
Publicado: (2019)

Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases
por: Miyoshi, Yasuhide, et al.
Publicado: (2016)

Lack of an association between the aPKCλ/ι expression in prostate cancer and the patient outcomes
por: Yokomizo, Yumiko, et al.
Publicado: (2017)

Sperm cryopreservation before definitive therapy for early‐stage prostate cancer: A single institution experience
por: Miyoshi, Yasuhide, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy
por: Kawahara, Takashi, et al.
Publicado: (2016)

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012)

Skene duct adenocarcinoma in a patient with an elevated serum prostate-specific antigen level: a case report
por: Tsutsumi, Sohgo, et al.
Publicado: (2018)

Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade
por: Yokomizo, Yumiko, et al.
Publicado: (2016)

Clear cell adenocarcinoma of the prostatic urethra: A case report
por: Sugimura, Rumiko, et al.
Publicado: (2018)

Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy
por: Ohtake, Shinji, et al.
Publicado: (2016)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

Increased neutrophil-to-lymphocyte ratio is associated with disease-specific mortality in patients with penile cancer
por: Kasuga, Jun, et al.
Publicado: (2016)

Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score
por: Kawahara, Takashi, et al.
Publicado: (2016)

The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday
por: Kawahara, Takashi, et al.
Publicado: (2019)

Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia
por: Kawahara, Takashi, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer
por: Nepal, Sat Prasad, et al.
Publicado: (2023)

Neutrophil–lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer
por: Sundar, Santhanam, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tb297rh7r7ovej979nfv7bh8bt